Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct;35(10):2903-2904.
doi: 10.1038/s41433-020-01209-y. Epub 2020 Oct 1.

Comment on "New anti-hyperglycaemic agents for type 2 diabetes and their effects on diabetic retinopathy"

Grace Xiao  1 , Albert S Li  2
Affiliations
Comment

Comment on "New anti-hyperglycaemic agents for type 2 diabetes and their effects on diabetic retinopathy"

Grace Xiao et al. Eye (Lond). 2021 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Comment on

References

    1. Saw M, Wong VW, Ho IV, Liew G. New anti-hyperglycaemic agents for type 2 diabetes and their effects on diabetic retinopathy. Eye. 2019;33:1842–51. doi: 10.1038/s41433-019-0494-z. - DOI - PMC - PubMed
    1. Marso SP, Holst AG, Vilsbøll T. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl J Med. 2017;376:891–2. - PubMed
    1. Wang T, Lu W, Tang H, Buse JB, Stürmer T, Gower EW. Assessing the association between GLP-1 receptor agonist use and diabetic retinopathy through the FDA adverse event reporting system. Diabetes Care. 2019;42:e21–3. doi: 10.2337/dc18-1893. - DOI - PMC - PubMed
    1. Li AS, Pomeranz HD. Food and drug administration adverse event reports of retinal vascular occlusions associated with phosphodiesterase type 5 inhibitor use. J Neuroophthalmol. 2016;36:480–1. doi: 10.1097/WNO.0000000000000450. - DOI - PubMed
    1. The Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the diabetes control and complications trial. Arch Ophthalmol. 1998;116:874–86. doi: 10.1001/archopht.116.7.874. - DOI - PubMed

MeSH terms

Substances